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Anand Shah and Scott R Henderson (AS and
SRH): a 72-year-old retired male physician was
referred with poorly controlled asthma, necessitat-
ing oral glucocorticoid therapy. He had been diag-
nosed with occupational asthma 9 years earlier
with initially good control on an inhaled cortico-
steroid (ICS). In the preceding year, his symptoms
deteriorated with increasing wheeze, dyspnoea and
persistent productive cough with 5 mL sputum
daily associated with reduced exercise tolerance of
30–50 metres on the ﬂat. He also reported a post-
nasal drip and allergic rhinitis. Medical history
included two nasal polypectomies and paroxysmal
tachycardias, with normal 24 h Holter, echocardio-
gram and exercise tolerance test.
He had previously worked as an occupational
physician for 15 years, monitoring coffee bean
handlers for asthma and sensitivity to Aspergillus
spp, commonly found in coffee bean cargoes.
Interestingly, he himself was indirectly exposed to
coffee bean dust (including green coffee beans
prior to roasting and castor bean dust) through his
interaction with workers and his place of work. He
then developed asthma symptoms 6 years after
taking up his Occupational Physician post, consist-
ent with a diagnosis of occupational asthma, and a
series of skin prick tests demonstrated sensitivity to
Aspergillus fumigatus.
Examination at presentation revealed no signiﬁ-
cant abnormalities. Investigations showed FEV1 of
1.5 L (45% predicted), FVC of 3.0 (63% pre-
dicted) and peak expiratory ﬂow (PEF) of 280 L/
min (predicted). Sputum cytology revealed 12%
eosinophils. Total IgE was elevated at 219 (0–
120) kU/L with Aspergillus radioallergosorbent
test (RAST) at 4.05 (0–0.34) IU/mL. Peripheral
eosinophil count, on prednisolone, was normal.
Skin prick tests were positive to A. fumigatus,
grass mixture and house dust mite. Chest radio-
graph was unremarkable.
Philip W Ind (PWI): lung function tests demon-
strated an obstructive defect with an FEV1:FVC
ratio of 50% and reduced PEF. In addition to prob-
able IgE-related occupational asthma, his previous
allergen exposure, documented immune reactivity
to Aspergillus spp and failure to respond to conven-
tional therapy raise the possibility of allergic
bronchopulmonary aspergillosis (ABPA). The pos-
sible differential diagnosis of continued exposure
to workplace allergens resulting in worsening of his
condition did not apply as he was retired.
He was intolerant of long-acting β2 agonists,
theophylline was relatively contraindicated by pre-
vious tachycardias and a tapering dose of prednisol-
one and high-dose ICS may be inadequate to
control symptoms. A leukotriene antagonist (LTRA)
was tried in view of his nasal symptoms. High reso-
lution CT scan (HRCT) was also arranged to evalu-
ate lung parenchyma.
Susan J Copley (SJC): thoracic HRCT demon-
strated right middle lobe and left lower lobe bron-
chiectasis (ﬁgure 1) which could be consistent with
ABPA.
AS and SRH: LTRA therapy was complicated by
a severe rash over the legs that resolved on stopping
the medication. Tapered prednisolone and high-
dose ICS produced improvement. However,
3 months later, he re-presented with a 5-week
history of severe muscle cramps, radiating from the
buttocks to the lower legs. There was no associated
urinary retention and no loss of perianal sensation,
but he noted paraesthesia of both hands and feet
and drenching night sweats. Neurological examin-
ation revealed reduced power (4+/5) in shoulder
abduction, hip ﬂexion and hip extension bilaterally,
and diminished pinprick sensation over the fourth
and ﬁfth ﬁngers in both hands and in a stocking
distribution in his legs.
Investigations at this time showed elevated total
white cell count of 17.5×109/L with peripheral
eosinophilia of 7.1×109/L and elevated C reactive
protein of 71 (0–10 mg/L). Multiple sputum
samples were negative for bacteria and fungi. Chest
X-ray was again normal. MRI of the spine did not
reveal any neural compression, but mild degenera-
tive changes. Antineutrophil cytoplasm antibody
(ANCA) was positive with perinuclear immuno-
ﬂuorescence staining pattern (p-ANCA) and ELISA
demonstrated elevated antimyeloperoxidase (MPO)
antibody titre of 107 AU/mL (0–30).
Alan D Salama (ASD): the history of severe
myalgia with peripheral neuropathy and elevated
inﬂammatory markers suggests the possibility of a
systemic inﬂammatory process such as vasculitis.
Previous history of worsening asthma, nasal polyps,
elevated eosinophil count and positive ANCA with a
speciﬁc anti-MPO antibody is consistent with eosino-
philic granulomatosis with polyangiitis (EGPA). It is
important to conﬁrm the diagnosis histologically, if
possible, and explore the extent of the disease. The
patient’s urine showed no evidence of blood or
protein on dipstick testing. In addition, there were
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no cells or casts seen on microscopy. With a bland urine sediment,
the most useful way to obtain a tissue diagnosis would be sural
nerve biopsy.
H Terence Cook (HTC): sural nerve biopsy (ﬁgure 2) shows
two epineural arteries with ﬁbrosis and luminal narrowing. One
of these is surrounded by eosinophils. The appearances are con-
sistent with arterial vasculitis, but there is no active ﬁbrinoid
necrosis in this specimen. The presence of eosinophils is consist-
ent with EGPA.
PWI: this patient has evidence of both ABPA and EGPA
which may have occurred in relatively quick succession.
Immunosuppression is important in managing both these condi-
tions, and the patient should be started on a combination of a
glucocorticoid and a steroid sparing agent such as azathioprine.
AS and SRH: this patient’s clinical symptoms markedly
improved following immunosuppression with prednisolone
60 mg and azathioprine 100 mg. Anti-MPO antibody titres and
inﬂammatory markers diminished rapidly and normalised after
2 months’ treatment. He continues to do well with maintenance
low-dose prednisolone and azathioprine and high-dose ICS. It
is, however, unclear whether his occupational asthma and diag-
nosis of ABPA and EGPA are pathologically linked.
PWI: ABPA represents a severe complication of A. fumigatus
sensitisation which, in this patient, is likely to be related to pro-
longed occupational exposure to Aspergillus from coffee beans,
leading to an IgE-directed immune response resulting in airway
and parenchymal lung damage. Premorbid occupational asthma
and atopic symptomatology support the patient’s increased sus-
ceptibility to ABPA, the most common antigen-speciﬁc hyper-
sensitivity disorder within the UK. In addition, a latency period
can exist between exposure to coffee bean dust, A. fumigatus
sensitivity and occupational asthma. This would be consistent
with his occupational asthma initially occurring 6 years after
exposure to the coffee bean plantation, and an additional
disease process evolving 9 years later, such as the development
of ABPA.
However, the association between ABPA and the emergence
of Churg Strauss syndrome (CSS) is extremely unusual. To my
knowledge, only two cases of ABPA ‘progressing’ to allergic
granulomatosis and angiitis or EGPA have been reported.1 2 The
precise mechanism(s) by which ABPA and possibly other allergic
mycoses could relate to a systemic vasculitis such as EGPA are
unclear. Both show evidence of disordered humoral immunity,
with IgE elevation in allergic mycoses and presence of ANCA in
some patients with EGPA; however, these are generally IgG iso-
types. Eosinophilic reactivity is present in both but is most
marked in cases of EGPA.
ASD: autoantibodies, in particular antibacterial permeability
increasing protein, are associated with infective lung disease
such as cystic ﬁbrosis and non-cystic ﬁbrosis bronchiectasis. It is
noteworthy that ANCA can also be a feature of infective lung
disease. In the same way that reducing bacterial load is import-
ant, treatment of fungal colonisation/infection with anti-fungals
(in addition to glucocorticoids) was considered in this patient
with the aim of reducing inﬂammatory processes resulting in
autoantibody production.
Numerous A. fumigatus antigens are recognised that stimulate
both humoral and cellular immune responses mediated directly
and indirectly by allergens binding to IgE/IgG and stimulating
CD4+ Th2 cell subsets. Human leucocyte antigen (HLA) asso-
ciation has been found in ABPA, in small cohort studies, with
increased frequencies of HLA-DR2 and DR5. Although recent
data have also demonstrated genetic risk factors for EGPA,
including HLA-DR genes (HLA-DRB4) and interleukin-10 pro-
duction, the precise trigger initiating EGPA is unknown.
Eotaxin-3, an eotactic chemokine (CCL26), has been shown to
be a very speciﬁc marker in EGPA and may be a useful bio-
marker for disease monitoring, but whether elevated levels
Figure 1 Coronal (A) and sagittal (B and C) CT reconstructions demonstrating right middle lobe (C) and left lower lobe (A and B) bronchiectasis
(arrows) consistent with allergic bronchopulmonary aspergillosis.
Figure 2 Sural nerve biopsy showing two epineural arteries with
ﬁbrosis and luminal narrowing. One of these is surrounded by
eosinophils. The appearances are consistent with arterial damage from
vasculitis, but there is no active ﬁbrinoid necrosis. The presence of the
eosinophils is consistent with eosinophilic granulomatosis with
polyangiitis.
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occur in patients with EGPA in response to certain environmen-
tal antigens, such as Aspergillus, is unknown.3 However, it is of
interest to note that eotaxin-3 was shown to be the only eotaxin
upregulated in asthmatics following respiratory allergen chal-
lenge,4 lending support to the notion that certain allergens may
provoke production of this chemokine, which, in genetically
susceptible individuals, may promote excessive eosinophilic
recruitment and damage.
The pathogenic signiﬁcance of anti-MPO autoantibodies,
found in 30%–40% of patients with EGPA at diagnosis, is less
established. Presence of anti-MPO antibodies has a closer associ-
ation with microscopic polyangiitis, presenting with necrotising
glomerulonephritis, alveolar haemorrhage, purpura and mono-
neuritis multiplex. A previous suggestion of cross-reactivity
between MPO and eosinophilic peroxidise has not been con-
ﬁrmed. Therefore, there may be common antigen/allergen pres-
entation in genetically susceptible individuals mediating both
ABPA and EGPA; however, this association remains uncommon.
Of note, we did not measure this patient’s eotaxin-3 level or
have his HLA-DR typing.
Charles D Pusey (CDP): another possible link is the use of
LTRA therapy in the management of ABPA. Numerous cases of
EGPA have been reported following the introduction of LTRAs
for the management of asthma. Although this association has
often been attributed to therapeutic withdrawal or cessation of
corticosteroids, unmasking EGPA, an increasing number of cases
have since been reported showing a spectrum of EGPA develop-
ment in the presence and absence of concomitant corticosteroid
use. Recent systematic review of this possible iatrogenic associ-
ation demonstrated a clear temporal relationship between
LTRAs and onset of EGPA.5 The exact mechanism by which
LTRAs may induce EGPA remains unknown, and there is a dis-
tinct lack of experimental work to guide understanding.
Nonetheless, the occurrence of 63 cases of EGPA on LTRAs,
reported to the Committee on Safety of Medicines, over the last
30 years highlights the need for cautious introduction of select-
ive cys-LT1 receptor antagonists in patients with severe asthma.
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